Now that we are on the NASDAQ, what we need now is a "buy" recommendation from some big boy brokerage firm, then we are on our way to becoming more noticeable to prospective investors. Being on OTC, they were not going to be touched by such firms. Articles like recently published in Lancet could make such a thing possible.
News 
Market Data 
Discover 
